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Abstract 
Aims/hypothesis: Potentiation of glucose-induced insulin secretion is the main mechanism of exenatide (EXE) anti-
diabetic action, however, increased glucose utilization by peripheral tissues has been also reported. We here studied 
the effect of EXE on glucose uptake by skeletal muscle cells.
Methods: 2-deoxy-glucose (2DG) uptake and intracellular signal pathways were measured in rat L6 skeletal muscle 
myotubes exposed to 100 nmol/l EXE for up to 48 h. Mechanisms of EXE action were explored by inhibiting AMPK 
activity with compound C (CC, 40 μmol/l) or siRNAs (2 μmol/l).
Results: Time course experiments show that EXE increases glucose uptake up to 48 h achieving its maximal effect, 
similar to that induced by insulin, after 20 min (2- vs 2.5-fold-increase, respectively). Differently from insulin, EXE 
does not stimulate: (i) IR β-subunit- and IRS1 tyrosine phosphorylation and binding to p85 regulatory subunit of PI-
3kinase; (ii) AKT activation; and (iii) ERK1/2 and JNK1/2 phosphorylation. Conversely, EXE increases phosphorylation of 
α-subunit of AMPK at Thr172 by 2.5-fold (p < 0.01). Co-incubation of EXE and insulin does not induce additive effects 
on 2DG-uptake. Inhibition of AMPK with CC, and reduction of AMPK protein expression by siRNA, completely abolish 
EXE-induced 2DG-uptake. Liraglutide, another GLP-1 receptor agonist, also stimulates AMPK phosphorylation and 
2DG-uptake. Moreover, EXE stimulates 2DG-uptake also by L6 myotubes rendered insulin-resistant with methylglyoxal. 
Finally, EXE also induces glucose transporter Glut-4 translocation to the plasma membrane.
Conclusions/interpretation: In L6 myotubes, EXE and liraglutide increase glucose uptake in an insulin-independent 
manner by activating AMPK.
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Background
Glucagon-like peptide-1 (GLP-1) is a gut hormone 
secreted by intestinal L cells into the bloodstream in 
response to nutrient ingestion and, together with the 
glucose-dependent insulinotropic peptide (GIP), belongs 
to the incretins family [1, 2]. Exenatide (EXE) is the 
synthetic analog of exendin-4, a GLP-1 homologous 
originally purified from the salivary glands of the lizard 
Heloderma suspectum, and it is currently employed in the 
treatment of type 2 diabetes (T2D) [3, 4]. In contrast to 
GLP-1, which is rapidly cleaved by the dipeptidyl pepti-
dase IV (DPP-IV) into its inactive form, EXE is resist-
ant to the proteolytic effect of DPP-IV, has comparable 
effects on insulin secretion and exerts a more potent 
blood glucose lowering effect [3–7].
GLP-1 and EXE stimulate glucose-dependent insulin 
secretion and decrease glucagon release after binding 
to the GLP-1 Receptor (GLP-1R) present on pancreatic 
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endocrine β- and α-cells [8, 9]. The GLP-1R is coupled 
to a G protein that, once activated, increases intracel-
lular cyclic AMP (cAMP) and induces activation of 
protein kinase A (PKA), extracellular signal-regulated 
kinase (ERK)1/2 and phosphoinositol 3 kinase (PI3K)/
protein kinase B (PKB) [10–12]. It has been previously 
shown that GLP-1 exerts also an insulin-sensitizing 
effect by stimulating the uptake of glucose via the acti-
vation of PI3K, AKT and p70s6 k, whereas EXE seems 
to share only in part this capability in human myocytes 
[13–16].
The heterotrimeric protein AMPK, consisting of a cat-
alytic α and regulatory β and γ subunits, is ubiquitously 
expressed and it is regulated by a variety of physiological 
stimuli and drugs such as metformin and thiazolidinedi-
ones and plays a pivotal role in the regulation of mito-
chondrial biogenesis, fatty acid synthesis and glucose 
uptake [17]. Experiments performed in human skeletal 
muscle cells have shown that AMPK activation, through 
phosphorylation at threonine 172 (T172) of the α subu-
nit and subsequent phosphorylation of TBC1D4 (AS160) 
and TBC1D1, induces the translocation of the glucose 
transporter Glut-4 to the plasma membrane [18–22].
To learn more about the influence of GLP-1R agonists 
administration on peripheral glucose utilization, we here 
studied the effects of EXE and liraglutide (lira) on the 
molecular mechanisms leading to glucose uptake in rat 
L6 myotubes.
Methods
Reagents
Media, sera and antibiotics for cell culture were from 
Lonza (Walkersville, MD, USA). Protein electrophoresis 
and western blot reagents were from Bio-Rad (Richmond, 
VA, USA) and electrochemiluminescence reagents from 
Pierce (Rockford, IL, USA). Insulin was from Eli Lilly 
(Florence, Italy). The antibodies used were: anti-GLP-1 
receptor (kind gift of Drs. Wanda Dolci and Bernard 
Thorens [10, 23], anti-insulin receptor (IR), anti-p-tyros-
ine (Biosource, Camarillo, CA), anti-IRS-1 (Millipore, 
Billerica, MA, USA), anti-p85 subunit of PI3-kinase, anti-
Akt, anti-p-Akt S473, anti-p-AMPK T172, anti-AMPK, 
anti-p-ACC S78/80, anti-ACC, anti-p-JNK T183/Y185, 
anti-JNK, anti-p-AS160T642, anti-AS160 (Cell Signaling 
Technology, Beverly, MA, USA), anti-ERK1/2, anti-p-
ERK1/2 (Santa Cruz, CA, USA), anti-GLUT4 antibod-
ies [24], and anti-αTubulin (Sigma, St Louis, MO, USA). 
5-amino-4-imidazole carboxamide riboside (AICAR), 
Compound C, and LY294002 were from Calbiochem (La 
Jolla, CA). SiRNAs were from Riboxx (Radebeul, Ger-
many). Methylglyoxal (MGO) was from SIGMA-Aldrich 
(St Louis, MO, USA). Exenatide and liraglutide were kind 
gifts from Amylin and Novo Nordisk, respectively.
Cell culture, treatment and transfection of siRNAs
Rat L6 skeletal muscle myoblasts were grown in complete 
high glucose DMEM (with l-glutamine) supplemented 
with 10 % (vol/vol) inactivated fetal calf serum and 1 % 
(vol/vol) antibiotics-antimycotics and maintained in 
a humidified atmosphere of 5 % CO2 in air at 37 °C. L6 
myotubes were allowed to differentiate as described 
previously [25, 26]. Myotubes were treated with EXE 
100 nmol/l for 20 min and 2, 4, 24 and 48 h, or with insu-
lin 100  nmol/l for 30  min. Where indicated, cells were 
treated with AICAR 2 mmol/l for 2 h, or pre-treated with 
CC 40 μmol/l for 30 min, with LY 25 μmol/l for 30 min, 
methylglioxal 2.5 mmol/l for 30 min. L6 myotubes were 
also transfected with siAMPK-1, -2 and -3 targeting both 
AMPK α 1 and 2, using Oligofectamine Reagent from 
Life Technologies (Carlsbad, CA) according to the manu-
facturer’s instructions as previously described [27]. SiNR 
was used as negative control.
Western blot analysis
Baboons tissues and human skeletal muscle proteins 
were extracted as previously described [28, 29]. α-TC1 
and β-TC3 cell lines were a kind gift of prof. Douglas 
Hanahan [30]. L6 myotubes protein were obtained by 
lysing cells in buffer containing 50  mmol/L HEPES (pH 
7.5), 150  mmol/L NaCl, 10  mmol/L EDTA, 1  % Tri-
ton X-100, 10  mmol/L Na4P2O7, 100  mmol/L NaF, and 
2  mmol/L sodium orthovanadate supplemented with 
protease inhibitors cocktail. Protein concentration was 
determined with the Bradford assay (DC Protein Assay; 
Bio-Rad, Hercules, CA) according to the manufactur-
er’s instructions. For the immunoprecipitation proto-
col, equal amounts of proteins (300  µg) were incubated 
at 4  °C overnight with anti-IRS1 antibody; immune 
complexes were collected by incubation with protein 
A-sepharose for 3 h at 4 °C and resuspended in Laemmli 
buffer. Equal amounts of proteins resolved by SDS-PAGE 
were electrophoretically transferred to nitrocellulose 
membrane (Amersham Biosciences, Piscataway, NJ). The 
membranes were incubated with primary antibodies fol-
lowed by incubation with peroxidase-conjugated second-
ary antibodies. Proteins were detected by using enhanced 
chemiluminescence (Amersham Biosciences, Piscataway, 
NJ), and band densities were quantified by densitom-
etry. To normalize the blots for protein levels, after being 
immunoblotted with antiphosphospecific antibodies, the 
same blots were stripped and re-probed with appropri-
ate primary antibodies. To assess Glut 4 translocation 
to the plasma membrane upon EXE treatment, plasma 
membrane proteins were extracted from L6 myotubes 
by the use of “Mem-PER Plus Membrane Protein Extrac-
tion Kit” (Thermo Fisher Scientific, Rockford, IL, USA) 
following the manufacturer instructions. Equal amount 
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of protein extracts were then analyzed by western blot as 
previously described in this section.
Determination of 2‑deoxyglucose (2DG) uptake
2-DG uptake measurements were carried out as 
described previously [25, 26]. Myotubes were starved 
for 24  h and, subsequently, treated with hormones or 
chemical compounds. Cells were supplemented during 
the final 10 min with 0.2 mmol/L 2-DG and then solubi-
lized. 2-DG uptake was quantified by liquid scintillation 
counting.
Gene expression analysis
Total RNA was obtained from L6 myotubes, reverse 
transcribed using the high capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA) and 
analyzed by Real-Time quantitative PCR using a Power 
SYBR Green PCR Master Mix (Applied Biosystems, Foster 
City, CA) with 10 ng of cDNA and 0.3 uM of the following 
oligonucleotide primers: GLUT4 FW: 5′-CCACAGAAAG 
TGATTGAACAGAGC-3′ GLUT4 RV: 5′-AATGATGCC 
AATGAGAAAGGAG-3′. The rat beta-2 microglobulin 
(B2M) was amplified and used to normalize the results 
according to the Livak method, with the following oligo-
nucleotide primers: B2M FW: 5′-ACTGAATTCACACCC 
ACCGA-3′; B2 m rv: 5′-attacatgtctcggtcccaggt-3′.
Statistical analysis
All results are given as mean ± SD. Statistical differences 
were assessed by Student’s t test and ANOVA. A p ≤ 0.05 
was considered statistically significant.
Ethics
All animal studies (non-human primate) were approved 
by the Texas Biomedical Research Institute Animal Care 
and the Use Committee as well as the University of Texas 
Health Science Center at San Antonio (San Antonio, 
TX, USA), Institutional Animal Care and Use Commit-
tee. Human studies were approved by the Institutional 
Review Board of University of Texas Health Science 
Center at San Antonio (San Antonio, TX, USA).
Results
Glp‑1 receptor expression in different species and tissues
EXE, as well as other GLP-1 receptor agonists, exert their 
function by binding to the GLP-1R. Thus, we evaluated 
by Western Blot analysis whether GLP-1R protein was 
expressed in undifferentiated (myoblast) and differen-
tiated (myotubes) L6 rat skeletal muscle cells. Baboon 
adipose tissue, skeletal muscle, liver and brain, human 
gastrocnemius, α-TC1 and β-TC3 cell lines were used 
as control of expression. GLP-1R was highly expressed 
in myotubes with levels comparable to those observed 
in baboon brain (B). GLP-1R was also present in human 
gastrocnemius and in baboon skeletal muscle (M), adi-
pose (A) and liver (L) baboon tissues, in α- and β-TC3 
cells (Fig. 1a).
EXE induces 2‑deoxy‑d‑glucose (2DG) uptake in L6 
myotubes
Differentiated L6 cells were exposed to 100 nmol/l EXE 
from 20  min (acute stimulation) up to 48  h (chronic 
stimulation). Exposure to 100 nmol/l insulin for 30 min 
served as positive control. EXE induced a 2-fold increase 
in 2DG uptake already after 20  min and 2DG uptake 
remained steadily higher than in control untreated cells 
up to 48 h (Fig. 1b). Noteworthy, after acute stimulation, 
the effect of EXE did not differ from that of insulin. We 
then investigated whether the effect of EXE on glucose 
uptake was additive to that of insulin. Co-incubation with 
EXE and insulin did not further increase 2DG uptake as 
compared to either insulin or EXE alone (Fig. 1c).
EXE induces AMPKα activation in myotubes
We then investigated the molecular mechanisms 
involved in EXE-induced glucose uptake. Differentiated 
L6 muscle cells were treated with either EXE for 20 min, 
insulin for 30  min, or both. In contrast to insulin, EXE 
did not induce tyrosine phosphorylation of either IR 
β-subunit and IRS-1 (Fig.  2a, b). Because association of 
the p85 regulatory subunit of PI3K with tyrosine-phos-
phorylated IRS-1 is essential to promote downstream PI3 
kinase signaling, the effect of EXE on IRS-1 docking to 
p85 regulatory subunit of PI3K was examined by immu-
noprecipitation of IRS-1 from cell lysates followed by 
immunoblotting with anti-p85 antibodies. IRS-1 tyros-
ine phosphorylation following insulin stimulation caused 
increased association with the p85 regulatory subunit 
while this was not detected after EXE treatment (Fig. 2c). 
Furthermore, EXE did not activate AKT and its substrate 
GSK3β, as determined by assessing phosphorylation at 
Ser473 and Ser21/9 respectively (Fig.  3a, b). Addition-
ally, EXE treatment did not affect phosphorylation of 
ERK1/2 (Fig. 3a, b, c). Moreover, EXE stimulated AMPKα 
phosphorylation at Thr172 by 2.5 fold as compared to 
untreated control cells while insulin did not (Fig.  3d). 
Insulin and EXE did not exhibit additive effects on AKT 
or AMPK activation when used in combination (Fig. 3a, 
d), suggesting that EXE exerts its stimulatory effect on 
glucose uptake by an insulin-independent mechanism 
and possibly via AMPK activation.
EXE stimulates AMPKα in a time and dose dependent 
manner
The time course effect on AMPKα activation and activ-
ity was examined by exposing L6 myotubes to EXE for 
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20 min, and 2, 4, 24, and 48 h. AMPKα phosphorylation at 
Thr172 and AMPK substrate ACC at Ser78/80 were deter-
mined by western blot. EXE stimulated both AMPK and 
ACC phosphorylation already after 20  min of exposure 
and these stimulatory effects were maintained up to 48 h 
(Fig. 4a, b). EXE significantly stimulated AMPK phospho-
rylation in a dose-dependent manner from 1 to 100 nmol/l 
(Fig.  4c). Pre-treatment of L6 myotubes for 30  min with 
the AMPK inhibitor CC abolished the stimulatory effect 
of both EXE and 2  mmol/l AICAR (a chemical activator 
of AMPKα) on AMPKα and ACC phosphorylation (Addi-
tional file  1: Figure S1a, b). By contrast, the stimulatory 
effects of EXE and AICAR on AMPKα and ACC phospho-
rylation, were not affected by pre-treatment with the PI3 K 
inhibitor LY294002 (Additional file 1: Figure S1a, b) indi-
cating that EXE-induced AMPK activation is not mediated 
by the PI3K signaling pathway.
EXE induces 2DG uptake via AMPKα activation in myotubes
To further explore the role of AMPKα activation on EXE-
induced glucose uptake, 2DG uptake was measured in L6 
myotubes exposed for 30 min in the presence or absence 
of CC (40  µmol/l) or LY294002 (25  µmol/l) and then 
incubated with EXE, insulin or AICAR. CC pre-treat-
ment abolished glucose uptake stimulated by both EXE 
and AICAR (p  <  0.001) while insulin-induced glucose 
uptake was only partially inhibited (Additional file 1: Fig-
ure S1c). By contrast, LY294002 abolished insulin stimu-
lated glucose uptake while it did not impair neither EXE 
nor AICAR stimulated glucose uptake (p < 0.001; Addi-
tional file  1: Figure S1c). Altogether these data suggest 
that AMPKα activation by EXE induces glucose uptake.
Exposure of L6 myotubes for 30 min to CC (40 mmol/l) 
resulted in a marked reduction (p  <  0.001) of AMPK 
phosphorylation in response to acute (20 min) or chronic 
(48 h) treatment with EXE (Additional file 1: Figure S1d). 
Exposure to LY294002 for 30 min did not affect AMPK 
phosphorylation in response to EXE (Suppl. Figure  1d). 
Insulin stimulated AS160 phosphorylation at Thr642, 
while EXE did not (Fig.  5a). Interestingly however, EXE 
increased by ~70  % the phosphorylation of TBC1D1, a 
AS160 paralog, which is more abundantly expressed in 
skeletal muscle and more strongly phosphorylated by 
AMPK, as compared to AKT, downstream insulin sign-
aling [19–21]. This effect of EXE was abolished by its 
antagonist exendin 9–39 (Fig.  5b). Moreover exendin 
9–39, which specifically antagonizes EXE action by bind-
ing to the GLP1 receptor, completely abolished EXE-
induced AMPK phosphorylation (Fig.  5c). In addition, 
acute and chronic exposure to EXE did not change sig-
nificantly Glut-4 mRNA levels as well as protein expres-
sion (Additional file  2: Figure  2a, b). Conversely, EXE 
increased of about 6-fold the translocation of Glut-4 to 
the plasma membrane at both 20 min and 48 h, account-
ing for the increased 2D-glucose uptake observed after 
EXE stimulation (Additional file 2: Figure 2c). In order to 
demonstrate equal membrane protein loading we meas-
ured the β subunit of the IR which is a useful marker of 
plasma membrane proteins. Both GLUT4 and IR are 
located in the plasma membrane, and, as showed in 
Additional file 2: Figure 2c, no effects were reported on 
IR expression after treatment with EXE at short and long 
time of exposure.
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Fig. 1 GLP-1R expression in different species and tissues: a Murine 
endocrine islet cells (αTC1 and βTC3), rat L6 myoblast (Bl) and 
myotube (Tb), human skeletal muscle (M) and baboon adipose 
(A) muscle (M) liver (L) and brain (B). Time course of EXE-induced 
2DG uptake in L6 myotubes b Myotubes were stimulated with 
100 nmol/l for 20 min, and 2, 4, 24, and 48 h and with 100 nmol/l 
insulin (INS) for 30 min as control. Effects of co-incubation with EXE 
and insulin on 2DG-glucose uptake c Myotubes were stimulated with 
either 100 nmol/l EXE, 100 nmo/l INS and both. Data are shown as 
mean ± SD of three independent experiments. (*p < 0.001, **p < 0.01 
vs control)
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Effects of AMPKα silencing on EXE‑induced glucose uptake
The role of AMPK in EXE-mediated glucose uptake 
was further explored by AMPK silencing with siR-
NAs. AMPKα expression was reduced in L6 myotubes 
by using three different siRNAs targeting its α1 and 
the α2 catalytic subunits. Western blot analysis con-
firmed ~80  % down-regulation of AMPKα expression 
with the siRNA2 (p  <  0.001; Fig.  6a) together with a 
marked decrease of AMPKα phosphorylation at Thr172 
(p  <  0.001, Fig.  6b). EXE-induced glucose uptake was 
abolished in L6 myotubes transfected with AMPKα 
siRNA2 as compared with untreated control cells or 
cells transfected with siRNA NR (Fig.  6c). Silencing 
AMPKα by using siRNA2 did not affect basal glucose 
uptake as compared to cells transfected with siRNA NR 
(Fig. 6d).
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Fig. 2 IRβ/IRS1/p85 signaling pathway in L6 myotubes. Cells were stimulated with either 100 nmol/l EXE, 100 nmol/l INS and both. The cells were 
then lysed and equal amounts of total proteins were immunoprecipitated with anti-IRS-1 antibody and immunoblotted with antiphosphotyrosine 
antibody (a, b) and anti-p85 subunit of PI 3-kinase (c). To normalize for protein levels the blots were stripped and re-probed with anti-IRS-1 antibody 
(A and C, top panel). Data are shown as mean ± SD of three independent experiments. (*p < 0.01 vs control)
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Comparison of EXE and Liraglutide effects on glucose 
uptake
We also explored the possibility that lira, another GLP-
1R agonist, may act similarly to EXE on AKT and AMPK 
activation and 2DG uptake in L6 myotubes. Simi-
larly to EXE, Lira did not stimulate AKT phosphoryla-
tion (Fig.  7a) while stimulated AMPK phosphorylation 
(Fig. 7b) and glucose transport (Fig. 7c). These data futher 
support the role of AMPK phosphorylation as a mediator 
of EXE and Lira effects on glucose uptake.
Effects of EXE on MGO‑induced insulin resistance in L6 
myotube
L6 myotubes were rendered insulin resistant by using 
the AGE precursor MGO, an in  vitro model of chronic 
glucose toxicity induced by protein glycation [31]. Note-
worthy, EXE continued to stimulate glucose uptake in 
the presence of MGO, while insulin-stimulated glucose 
uptake in MGO treated cells was completely abolished 
(Fig. 8). These data further support the evidence that, in 
muscle cells, EXE-induced glucose transport is mediated 
by a molecular pathway different form that involved by 
insulin, and that this pathway is unaffected by MGO.
Discussion
T2D is a chronic disease characterized by hyperglycemia, 
insulin resistance, defective insulin secretion and islet 
of Langerhans remodeling [28, 29, 32, 33]. The intesti-
nal incretin GLP-1 also regulates glucose homeostasis in 
response to dietary fat and carbohydrate intake [4] and 
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Fig. 3 AMPKα activation in L6 myotubes. Cells were stimulated with either 100 nmol/l EXE, 100 nmol/l INS and both. After stimulation, whole 
lysates were immunoblotted with the phospho-specific antibodies: p-Akt S473 (a), p-GSK3β S21/9 (b), p-ERK1/2 T202/Y204 (c) and p-AMPK T172 
(d). In order to normalize for protein levels, blots were stripped and re-probed with anti-AKT, anti ERK1/2, anti-GSK3β and anti-AMPK antibodies. 
Data are shown as mean ± SD of three independent experiments. (*p < 0.001 vs basal)
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GLP-1 receptor (GLP-1R) agonists have become valuable 
tools in T2D treatment [34, 35].
Generally recognized mechanisms of GLP-1 and GLP-
1R agonists action are potentiation of glucose-induced 
insulin secretion, reduction of glucagon secretion, inhi-
bition of gastric emptying and decreased appetite [3, 
4, 8, 9], however, insulin sensitizing effects have been 
also described. Insulin-like effects of GLP-1 have been 
reported in adipose tissue [36–38] and muscle cell lines 
[39, 40] and insulin sensitizing effects of the GLP-1R ago-
nist EXE have been studied in animal models [41, 42] as 
well as in T2D subjects [43].
Previous studies in rodent [14, 44] and human cell 
lines [16] have shown that GLP-1 and exendin-4 can 
stimulate glucose uptake. In L6 myotubes, exendin-4 
augments insulin-stimulated glucose uptake via a 
molecular pathway that requires PI3  K activation [14]. 
However, whether or not exendin-4 might also exert a 
direct stimulating effect on glucose uptake was never 
addressed in muscle cells. In order to address this ques-
tion, we studied the effect of the exendin-4 analog EXE, 
given alone and in combination with insulin, on the 
uptake of glucose by L6 myotubes. We also explored the 
molecular mechanisms involved in EXE-induced glucose 
uptake. Our data demonstrate that EXE induces glucose 
uptake by utilizing a molecular pathway different from 
the insulin stimulated PI3K/Akt/AS160 signaling cas-
cade. Indeed, we show that EXE has the capability to 
increase glucose uptake in muscle cells in the absence 
of insulin, and interestingly, to an extent comparable to 
insulin. By using CC, which is a potent chemical inhibi-
tor of AMPK and a number of other protein kinases 
[45], as well as a specific siRNA-mediated knockdown 
designed to reduce the protein expression of the α1 and 
α2 subunits of AMPK, we provide direct evidence that 
the stimulatory effect of EXE on glucose uptake is medi-
ated by: (i) AMPK activation; (ii) activation of the Rab 
GTPase-activating protein TBC1D1, a paralog of AS160, 
highly expressed in skeletal muscle [17, 21]; and (iii) 
translocation to the plasma membrane of the insulin-
dependent glucose transporter Glut-4 [15, 22].
The fact that EXE stimulates glucose transport via AMPK 
might appear in contrast with previous data obtained in 
other muscle cell lines stimulated with GLP-1 in which 
PI3K activation has been described [5, 16]. The involve-
ment of different pathways might be explained by the dif-
ferent relative abundance of PI3K and AMPK in human 
and mouse cell lines and the degree of cell differentiation.
AMPK is a heterotrimeric protein which mediates sev-
eral cellular processes, including stimulation of glucose 
- 20’ 2h 4hEXE 24h 48h
- 20’ 2h 4hEXE 24h 48h
- 10-7 EXE 10-8 10-9 
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c
Fig. 4 Time-course and dose–response experiments of EXE effects 
on AMPK and ACC phosphorylation in L6 cells. Phosphorylated 
and total (a, b, c, upper panels) ACC S78/80 (a) and AMPKa T172 (b) 
protein levels were measured in cells exposed to EXE for increasing 
time periods. For the dose response curve (c) cells were incubated for 
20 min with 0, 1, 10 and 100 nmol/l EXE. Thr172 phosphorylation and 
total levels of AMPK were shown. Each bar represents the mean ± SD 
of three independent experiments. (*P < 0.01 and **P < 0.02 vs. 
control)
Page 8 of 13Andreozzi et al. J Transl Med  (2016) 14:229 
uptake, mitochondrial biogenesis and inhibition of fatty 
acid synthesis via phosphorylation of ACC [19–22]. 
AMPK is known to regulate adipocyte metabolism, 
inflammation, and vascular function and defective AMPK 
activation is associated with insulin resistance and T2D 
[46–48]. Glucose transport relies on insulin stimulated 
AKT phosphorylation and PI3K activation, as well as an 
alternative pathway involving AMPK/Cbl-CAP signaling 
[49]. Studies in AMPK-α1 KO mice have shown that of the 
two catalytic subunits of AMPK, the isoform α1 is essen-
tial for stimulation of glucose uptake by the soleus muscle 
[50]. The involvement of AMPK, resulting in nitric oxide 
synthase activation, also accounts for the improvements 
in endothelial dysfunction observed after EXE treatment 
[51, 52]. Likewise EXE-mediated beneficial effects on car-
diac function are associated with AMPK activation [53].
Our findings are consistent with recent studies where 
EXE and Lira administration reduced fasting and postpran-
dial blood glucose levels, and improved insulin sensitivity, 
in subjects with type 1 diabetes with absent endogenous 
insulin secretion [5, 6]. Differently from a previous report 
where Lira enhanced insulin sensitivity [54], we show a 
direct effect of EXE and Lira on glucose transport in myo-
tubes and suggest that these GLP-1R agonists might regu-
late glucose homeostasis also in an insulin-independent 
manner through an AMPK-dependent pathway.
The lack of additive effects of EXE (and Lira) and insu-
lin on glucose uptake can be explained by considering that 
the final step of their mechanism of action involves Glut-4 
translocation to the plasma membrane which is already 
maximally stimulated by insulin. Our findings are in agree-
ment with a previous study where Lira was reported to 
induce Glut-4 translocation via AMPK activation in C2C12 
murine muscle cells over-expressing Glut-4, although in 
that study glucose transport was not evaluated [55].
It is important to note that EXE increases glucose 
uptake also in L6 myotubes previously treated with 
methylglyoxal (MGO), which is increased in hypergly-
cemic conditions and induces insulin resistance in these 
cells [31]. Altogether, our findings demonstrate that the 
GLP-1R agonists EXE and Lira increase glucose uptake 
by muscle cells in an insulin-independent manner.
p-AS160T642
AS160
a
EXE 20
+- - -INS
p-
A
S1
60
/A
S1
60
 le
ve
ls
(f
ol
d
in
cr
ea
se
ov
er
 b
as
al
)
*
- + -
- - +
’
EXE 48h
-
-
β
p-TBC1D1 b
-actin
1D
/β
-a
ct
in
le
ve
ls
#
* *
p-
T
B
C
(f
ol
d
in
cr
ea
se
ov
er
 b
as
al
)
β Actin
p-AMPKαT172
c
K
α
T
17
2/
A
M
P
K
 le
ve
ls
#
* *
p-
A
M
P
(f
ol
d 
in
cr
ea
se
ov
er
 b
as
al
)
EXE
EXE 9-39
- + - +
- - + +
Fig. 5 Effects of EXE (20 min or 48 h) and exendin 9–39 on AS-160, 
TBCD1D and AMPK in differentiated L6 cells. L6 myotubes were 
stimulated for 20 min with 100 nmol/l EXE, 100 nmol/l exendin 9–39 
or the combination of both. Where indicated cells were stimulated 
with 100 nmol/l INS for 30 min and 100 nmol/l EXE for 20 min or 48 h. 
The blots were probed with phospho-specific AS160 T642 (a), TBCD1 
(b) and AMPKα T172 (c). To normalize for protein levels, the blots were 
stripped and re-probed with β-actin antibodies. Each bar represents 
the mean ± SD of three independent experiments. (*p < 0.001 and 
**p < 0.01 vs. control; #p < 0.02 vs. EXE)
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Conclusions
We demonstrate that EXE and Lira directly stimulate glu-
cose uptake by skeletal muscle cells through AMPK and 
TBC1D1 phosphorylation and subsequent Glut-4 translo-
cation to the plasma membrane. The EXE induced glucose 
transport is not affected by MGO-induced non-enzymatic 
glycosylation which, conversely, impairs insulin-stimulated 
glucose transport. In type 2 diabetes mellitus which is char-
acterized by increased non-enzymatic protein glycosylation 
because of chronic hyperglycemia, GLP-1R agonists might 
also improve defective glucose transport and glycometa-
bolic control by stimulating AMPK phosphorylation.
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Fig. 6 EXE induces 2DG-uptake via AMPKα activation in L6 myotubes. L6 myotubes were transfected with specific AMPK siRNAs. After transfection, 
the cells were stimulated with 100 nmol/l EXE or 100 nmol/l INS. Proteins were then extracted and probed with AMPKα (a) and phospho-specific 
AMPKα T172 (b) antibodies. To normalize the blots for protein levels, the blots were stripped and re-probed with anti-tubulin (a, lower panel) and 
AMPKα antibodies (b, lower panel). 2DG-uptake was measured in cells after stimulation with INS or EXE (c). Data are represented as fold increase 
over control ± SD of three independent experiments (*p < 0.001, **p < 0.01 vs basal). 2DG-uptake was also measured in cells transfected with 
the AMPK siRNA 2 or control SiNR, before and after stimulation with EXE. Data are shown as fold increase over control ± SD of three independent 
experiments (d) (**p < 0.01 vs basal)
(See figure on next page.) 
Fig. 7 Effects of EXE and Lira on AMPK and AKT phosphorylation in differentiated L6 cells. After 20 min- and 48 h incubation with EXE and Lira, both 
at 100 nmol/l, levels of Thr172 (a) and Ser 473 (b) phosphorylation were measured. 2DG-uptake (c) was measured in L6 myotubes treated for 30 min 
with 100 nmol/l INS and 100 nmol/l EXE and Lira for 20 min and 48 h. Each bar represents the mean ± SD of three independent experiments as 
shown. (*p < 0.01 and **p < 0.02 vs. control)
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